Genmab A/S
GMAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $19 | $81 | $86 | $96 |
| - Cash | $2 | $8 | $8 | $10 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $17 | $73 | $79 | $88 |
| Revenue | $1 | $6 | $1 | $6 |
| % Growth | -82.6% | 719.8% | -88.9% | – |
| Gross Profit | $1 | $6 | $1 | $6 |
| % Margin | 94.3% | 93.8% | 94.1% | 94.8% |
| EBITDA | $1 | $3 | $0 | $2 |
| % Margin | 49.2% | 48.4% | 37.1% | 36.6% |
| Net Income | $0 | $2 | $0 | $4 |
| % Margin | 39.2% | 36.3% | 27.3% | 59.7% |
| EPS Diluted | 0.65 | 3.42 | 0.31 | 5.99 |
| % Growth | -81% | 1,003.2% | -94.8% | – |
| Operating Cash Flow | $1 | $0 | $2 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $1 | $0 | $2 | $0 |